Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.
Spyridoula Vasileiou, PhD, postdoctoral associate, Baylor College of Medicine, discusses the potential role of ALVR109, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019 (COVID-19).
A preclinical analysis evaluated the endogenous T-cell responses of COVID-19 patients who recovered from the virus without hospitalization, as well as the immune activity against potential SARS-CoV-2 target antigens. The goal of the study was to identify SARS-CoV-2 target antigens that had immunodominant recognition by immunocompetent individuals, Vasileiou explains.
The results of the analysis, which were presented virtually during the 2020 ASH Annual Meeting & Exposition, showed a mean 9.3±1-fold expansion of cells that were comprised almost exclusively of CD3+ T cells, with a mixture of cytotoxic and helper T cells. These cells had a phenotype consistent with effector function and memory potential, as evidenced by upregulation of the CD25, CD69, and CD28 activation markers and the expression of central and effector memory markers, with minimal PD-1 or TIM-3 expression.
Furthermore, the immune activity was confirmed with the IFNg ELIspot assay. This demonstrated that the immune response was mediated by CD4 and CD8 T-cell subsets. Moreover, the majority of interferon gamma–producing cells produced TNF-alpha characteristics, which were associated with superior clinical outcomes in vivo. These findings suggest that ALVR109 could be a potentially safe and effective treatment for patients with COVID-19, Vasileiou concludes.